Omega Therapeutics Q1 2024 GAAP EPS $(0.36) Misses $(0.35) Estimate, Sales $2.360M Beat $1.630M Estimate
Omega Therapeutics Q1 2024 GAAP EPS $(0.36) Misses $(0.35) Estimate, Sales $2.360M Beat $1.630M Estimate
Omega Therapeutics 2024年第一季度GAAP每股收益美元（0.36美元）未達到預期（0.35美元），銷售額2360萬美元超過16.3萬美元的預期
Omega Therapeutics (NASDAQ:OMGA) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.35) by 2.86 percent. The company reported quarterly sales of $2.360 million which beat the analyst consensus estimate of $1.630 million by 44.79 percent. This is a 357.36 percent increase over sales of $516.000 thousand the same period last year.
歐米茄療法（納斯達克股票代碼：OMGA）公佈的季度虧損爲每股0.36美元，比分析師普遍預期的0.35美元（0.35美元）低2.86％。該公司公佈的季度銷售額爲2360萬美元，比分析師普遍預期的16.3億美元高出44.79％。這比去年同期的51.6萬美元銷售額增長了357.36％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。